First Trust Advisors LP grew its stake in shares of Theravance Biopharma Inc (NASDAQ:TBPH) by 70.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,118 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the quarter. First Trust Advisors LP’s holdings in Theravance Biopharma were worth $723,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its stake in shares of Theravance Biopharma by 1.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 217 shares during the last quarter. Ameritas Investment Partners Inc. increased its position in Theravance Biopharma by 6.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 230 shares in the last quarter. SG Americas Securities LLC increased its position in Theravance Biopharma by 8.1% during the 2nd quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 443 shares in the last quarter. Legal & General Group Plc increased its position in Theravance Biopharma by 3.7% during the 2nd quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 576 shares in the last quarter. Finally, Zacks Investment Management increased its position in Theravance Biopharma by 4.6% during the 2nd quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 959 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

TBPH has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Robert W. Baird reissued a “sell” rating and set a $22.00 target price on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $41.86.

Theravance Biopharma Inc (NASDAQ TBPH) opened at $25.82 on Thursday. Theravance Biopharma Inc has a fifty-two week low of $23.15 and a fifty-two week high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.

ILLEGAL ACTIVITY NOTICE: “Theravance Biopharma Inc (TBPH) Shares Bought by First Trust Advisors LP” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/07/theravance-biopharma-inc-tbph-shares-bought-by-first-trust-advisors-lp.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.